Costs of Opportunistic Upper Gastrointestinal Endoscopy and the Economic Burden of Gastric Cancer Management

NCT07522320 | Active Not Recruiting

• 1 other identifier: 003
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

Data will be extracted from routinely collected hospital databases.

Conditions

Gastric Cancer (GC); Gastric Adenocarcinoma

Keywords

Screening; Gastric Cancer; economic

Outcome Measures

Primary Outcomes (3)

• Stage distribution at diagnosis

  Distribution of gastric cancer stages at diagnosis (Stage I-IV) according to TNM classification (expressed as percentage of patients per stage).

  At diagnosis (2015-2020)

• Treatment patterns

  Types of treatment received by patients with gastric cancer, including surgery, chemotherapy, radiotherapy, and palliative care

  During initial treatment period (2015-2020)

• Overall survival

  Overall survival of patients diagnosed with gastric cancer (measured in months).

  From diagnosis up to last follow-up (2015-2020)

Study Arms (1)

Cohort A - Opportunistic screening cohort

Cohort B - Gastric cancer cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Cohort A - Opportunistic screening cohort A cohort of FIT-positive individuals undergoing colonoscopy for colorectal cancer screening, with the addition of opportunistic EGD during the same procedure. Cohort B - Gastric cancer cohort A retrospective cohort including all patients diagnosed with gastric adenocarcinoma in the institution over a 10-year period.

You may qualify if:

• Cohort A:
• Eligible participants were adults aged 50 to 75 years or older who had been referred for colonoscopy as part of the national colorectal cancer screening programme, following a positive FIT. To be included, individuals also needed to provide informed consent and agree to undergo an EGD endoscopy for the screening of potential upper gastrointestinal precancerous conditions or lesions.
• Cohort B:
• Patients with gastric adenocarcinoma, diagnosed and treated at Unidade Local de Saúde do Alto Alentejo between 2015 and 2020.

You may not qualify if:

• Cohort A:
• Cohort B:
• Other types of gastric tumors.
• Gastric involvement from metastatic disease of another primary tumor.

Sponsors & Collaborators

• Unidade Local De Saúde Do Norte Alentejano: lead

Study Sites (1)

Unidade Local de Saúde do Alto Alentejo

Portalegre, 7300-060, Portugal

Location

Related Publications (5)

• Areia M, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J. 2018 Mar;6(2):192-202. doi: 10.1177/2050640617722902. Epub 2017 Jul 18.

  PMID: 29511549 BACKGROUND

• Lansdorp-Vogelaar I, Meester RGS, Laszkowska M, Escudero FA, Ward ZJ, Yeh JM. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol. 2021 Mar-Apr;50-51:101735. doi: 10.1016/j.bpg.2021.101735. Epub 2021 Feb 22.

  PMID: 33975689 BACKGROUND

• Mourato MB, Pratas N, Branco Pereira A, Tare F, Chanca R, Fronteira I, Dinis R, Areia M. Effectiveness of Gastric Cancer Endoscopic Screening in Intermediate-Risk Countries: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc. 2025 Feb 3;14:e56791. doi: 10.2196/56791.

  PMID: 39545590 BACKGROUND

• Mourato MB, Pratas N, Branco Pereira A, Costa Pinto F, Dinis R, Fronteira I, Areia M. Gastric Cancer Endoscopic Screening in an Intermediate-Risk Country-A Dual-Center Pilot Program. Helicobacter. 2025 Jul-Aug;30(4):e70061. doi: 10.1111/hel.70061.

  PMID: 40762368 BACKGROUND

• Ishii N, Shiratori Y, Ishikane M, Omata F. Population effectiveness of endoscopy screening for mortality reduction in gastric cancer. DEN Open. 2023 Sep 19;4(1):e296. doi: 10.1002/deo2.296. eCollection 2024 Apr.

  PMID: 37731836 BACKGROUND

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: March 27, 2026
• First Posted: April 13, 2026
• Study Start: January 2, 2026
• Primary Completion: April 3, 2026
• Study Completion (Estimated): May 20, 2026
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: 2015 to 2020

Locations

PT (1)